Purchase this article with an account.
Shigehiro Iwabuchi, Yuta Saito, Chiaki Sasaki, Hidetoshi Onda, Dai Ogino, Ryohei Koide; The Efficacy Of Intravitreal Bevacizumab For Macula Edema Of Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2012;53(14):923.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the efficacy of intravitreal bevacizumab (IVB) for macular edema with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
Subjects were 39 eyes of 39 consecutive patients (mean age, 68.6 ±10.5 years) in our hospital with macular edema from BRVO (24cases) or CRVO (15cases) treated by bevacizumab from Jan. 1st 2009 to Dec. 31st 2009. The patients were followed at least 3 months. Results were examined retrospectively by BCVA and macular thickness measured with optical coherence tomography (OCT).
Mean best-corrected visual acuity (BCVA) rose from 0.31 to 0.41 on 24 patients with BRVO who were treated by bevacizumab for macular edema. BCVA rose from 0.33 to 0.47 on 15 CRVO patients who were treated by bevacizumab for macular edema. Macular thickness improved from 516μm to 361μm on BRVO patients and from 552μm to348μm on CRVO patients. Patients who were treated by IVB within 30days after onset had better BCVA of 0.51 while those who were treated after 30 days had BCVA of 0.29.
Although these are retrospective study results, intravitreal bevacizumab was effective for maintaining good vision and decreased macular edema on retinal vein occlusion. It was more effective to treat by IVB within 30 days.
This PDF is available to Subscribers Only